1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 68, 394-424 (2018).
2. Petrick JL, McGlynn KA. The Changing Epidemiology of Primary Liver Cancer. Curr Epidemiol Rep. 6, 104-111 (2019).
3. Fox J. Cox proportional-hazards regression for survival data. See Also. 3, 371-372 (2002).
4. Carmona R, Zakeri K, Green G, et al. Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events. J Clin Oncol. 34, 1270-1277 (2016).
5. Melania Pintilie. Competing Risks: A Practical Perspective. Technometrics. 50, 411 (2008).
6. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 94, 496-509 (1999).
7. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67, 358-380 (2018).
8. Kongying Lin, Qizhen Huang, Zongren Ding, et al. Prognostic models for predicting overall and cancer-specific survival in hepatocellular carcinoma: A competing risk analysis. Research Square. https://doi.org/10.21203/rs.3.rs-46064/v1 (2020).
9. Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol. 11, 695-701 (2017).
10. Liu H, Cen D, Yu Y, et al. Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database? BMC Cancer. 18, 1125 (2018).
11. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 54, 463-471 (2011).
12. Liang L, Hu W, Yin X, et al. Adjuvant Intraportal Venous Chemotherapy for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombi Following Hepatectomy Plus Portal Thrombectomy World J Surg. 32, 627-631 (2008).
13. Fukuda S, Okuda K, Imamura M, et al. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 131, 300-310 (2002).
14. Kim do Y, Ahn SH, Kim SU, et al. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. Oncology. 81, 184-191 (2011).
15. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 133, 183-188 (1998).
16. Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 44, 891-895 (2006).
17. Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 17, 3137-3144 (2010).
18. Yamamoto M, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg. 83, 336-340 (1996).
19. JE Koo, JH Kim, YS Lim, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. International Journal of Radiation Oncology Biology Physics. 78, 180-187 (2010).
20. M Feng, E Ben Josef. Radiation therapy for hepatocellular carcinoma. Seminars in Radiation Oncology. 21, 271-277 (2011).
21. Cupino AC, Hair CD, Angle JF, et al. Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma? Gastrointestinal cancer research : GCR. 5, 13-17 (2012).
22. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31, 1237-1248 (1995).
23. Latouche A, Allignol A, Beyersmann J, et al. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 66, 648-53 (2013).
24. Wolkewitz M, Cooper BS, Bonten MJ, et al. Interpreting and comparing risks in the presence of competing events. BMJ. 349, g5060 (2014).
25. Jason C, Vincent P, Skye H, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 47, 435-442 (2000).
26. Ryoko Y, Naoki H, Tsugiko O, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 50, 785-794 (2015).
27. Jordi B, Ann-Lii C, Gerold M, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 67, 999-1008 (2017).